G1 Therapeutics (GTHX) News Today → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free GTHX Stock Alerts $3.40 -0.69 (-16.87%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 28 at 5:50 PM | msn.comG1 Therapeutics slips after new breast cancer data for lead assetMay 28 at 1:20 PM | marketbeat.comG1 Therapeutics (NASDAQ:GTHX) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $9.00 target price on shares of G1 Therapeutics in a research report on Tuesday.May 28 at 6:30 AM | globenewswire.comMeaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)May 26 at 7:06 AM | americanbankingnews.comInsider Selling: G1 Therapeutics, Inc. (NASDAQ:GTHX) Insider Sells 5,826 Shares of StockMay 25 at 4:35 PM | insidertrades.comMonica R. Thomas Sells 5,826 Shares of G1 Therapeutics, Inc. (NASDAQ:GTHX) StockMay 24, 2024 | marketbeat.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Insider Sells $24,877.02 in StockG1 Therapeutics, Inc. (NASDAQ:GTHX - Get Free Report) insider Monica R. Thomas sold 5,826 shares of G1 Therapeutics stock in a transaction that occurred on Thursday, May 23rd. The stock was sold at an average price of $4.27, for a total value of $24,877.02. Following the sale, the insider now directly owns 109,825 shares of the company's stock, valued at $468,952.75. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.May 24, 2024 | markets.businessinsider.comStrategic Licensing Agreements and Revenue Forecast Uphold Buy Rating for G1 TherapeuticsMay 23, 2024 | globenewswire.comG1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) MeetingMay 23, 2024 | americanbankingnews.comG1 Therapeutics (NASDAQ:GTHX) Receives "Buy" Rating from HC WainwrightMay 23, 2024 | americanbankingnews.comG1 Therapeutics (NASDAQ:GTHX) Earns Buy Rating from Needham & Company LLCMay 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Personalis (PSNL) and G1 Therapeutics (GTHX)May 22, 2024 | finance.yahoo.comG1 Therapeutics to Participate in TD Cowen’s 5th Annual Oncology Innovation SummitMay 22, 2024 | marketbeat.comG1 Therapeutics' (GTHX) "Buy" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $12.00 price objective on shares of G1 Therapeutics in a research note on Wednesday.May 22, 2024 | globenewswire.comG1 Therapeutics to Participate in TD Cowen's 5th Annual Oncology Innovation SummitMay 22, 2024 | markets.businessinsider.comG1 Therapeutics And Deimos Biosciences In License Deal For Lerociclib For Radioprotective UsesMay 22, 2024 | globenewswire.comG1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective UsesMay 16, 2024 | marketbeat.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Sees Significant Increase in Short InterestG1 Therapeutics, Inc. (NASDAQ:GTHX - Get Free Report) was the target of a significant growth in short interest in April. As of April 30th, there was short interest totalling 2,830,000 shares, a growth of 16.9% from the April 15th total of 2,420,000 shares. Based on an average trading volume of 1,140,000 shares, the short-interest ratio is currently 2.5 days.May 9, 2024 | msn.comG1 Therapeutics jumps amid takeover speculationMay 9, 2024 | msn.comWhat's Going On With G1 Therapeutics Stock?May 4, 2024 | finance.yahoo.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?May 3, 2024 | marketbeat.comFY2026 EPS Estimates for G1 Therapeutics, Inc. Reduced by HC Wainwright (NASDAQ:GTHX)G1 Therapeutics, Inc. (NASDAQ:GTHX - Free Report) - Investment analysts at HC Wainwright reduced their FY2026 earnings estimates for shares of G1 Therapeutics in a research report issued to clients and investors on Thursday, May 2nd. HC Wainwright analyst E. White now expects that the company wilMay 3, 2024 | finance.yahoo.comG1 Therapeutics First Quarter 2024 Earnings: Revenues DisappointMay 2, 2024 | marketbeat.comG1 Therapeutics (NASDAQ:GTHX) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPSG1 Therapeutics (NASDAQ:GTHX - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). G1 Therapeutics had a negative return on equity of 106.04% and a negative net margin of 58.13%. The firm had revenue of $14.48 million during the quarter, compared to the consensus estimate of $15.21 million. During the same period in the previous year, the company posted ($0.53) EPS.May 2, 2024 | marketbeat.comHC Wainwright Reiterates Buy Rating for G1 Therapeutics (NASDAQ:GTHX)HC Wainwright reissued a "buy" rating and set a $9.00 target price on shares of G1 Therapeutics in a research note on Thursday.May 2, 2024 | markets.businessinsider.comOptimistic Buy Rating for G1 Therapeutics Amidst Solid Financial Footing and Cosela’s Market ExpansionMay 2, 2024 | finance.yahoo.comG1 Therapeutics Inc (GTHX) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth ...May 1, 2024 | finance.yahoo.comQ1 2024 G1 Therapeutics Inc Earnings CallMay 1, 2024 | markets.businessinsider.comEvaluating G1 Therapeutics: Insights From 5 Financial AnalystsMay 1, 2024 | globenewswire.comG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2024 | msn.comGTHX Stock Earnings: G1 Therapeutics Beats EPS, Misses Revenue for Q1 2024May 1, 2024 | marketbeat.comNeedham & Company LLC Reiterates "Buy" Rating for G1 Therapeutics (NASDAQ:GTHX)Needham & Company LLC reaffirmed a "buy" rating and set a $12.00 price objective on shares of G1 Therapeutics in a research report on Wednesday.May 1, 2024 | msn.comG1 Therapeutics reports mixed Q1 results; reaffirms FY24 outlookMay 1, 2024 | finance.yahoo.comG1 Therapeutics Inc (GTHX) Q1 2024 Earnings: Close Alignment with Analyst Revenue ProjectionsMay 1, 2024 | globenewswire.comG1 Therapeutics Provides First Quarter 2024 Financial Results and Operational HighlightsMay 1, 2024 | globenewswire.comG1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for LerociclibApril 30, 2024 | markets.businessinsider.comHere's what Wall Street expects from G1 Therapeutics's earningsApril 30, 2024 | msn.comG1 Therapeutics Q1 2024 Earnings PreviewApril 30, 2024 | marketbeat.comabrdn plc Acquires Shares of 423,869 G1 Therapeutics, Inc. (NASDAQ:GTHX)abrdn plc bought a new position in G1 Therapeutics, Inc. (NASDAQ:GTHX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 423,869 shares of the company's stock, valued at approximately $1,293,000. abrdn plc owned about 0.82% of G1April 24, 2024 | marketbeat.comG1 Therapeutics (GTHX) Set to Announce Quarterly Earnings on WednesdayG1 Therapeutics (NASDAQ:GTHX) will be releasing earnings before the market opens on Wednesday, May 1, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=585617)April 19, 2024 | finance.yahoo.comG1 Therapeutics, Inc.'s (NASDAQ:GTHX) Shift From Loss To ProfitApril 18, 2024 | marketbeat.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Shares Sold by Raymond James & AssociatesRaymond James & Associates cut its stake in shares of G1 Therapeutics, Inc. (NASDAQ:GTHX - Free Report) by 38.9% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 565,555 shares of the company's stock after selling 360,221 shares during theApril 17, 2024 | finance.yahoo.comG1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024April 17, 2024 | globenewswire.comG1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024April 12, 2024 | markets.businessinsider.comBuy Rating for G1 Therapeutics: Market Position and Growth Potential Solidify Investment AppealApril 12, 2024 | markets.businessinsider.comBreaking Down G1 Therapeutics: 5 Analysts Share Their ViewsApril 12, 2024 | marketbeat.comG1 Therapeutics (NASDAQ:GTHX) Given "Buy" Rating at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $12.00 price target on shares of G1 Therapeutics in a research report on Friday.April 4, 2024 | globenewswire.comG1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceApril 1, 2024 | globenewswire.comG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 22, 2024 | marketwatch.comG1 Therapeutics Cuts Executive Salaries by 10% Amid Cost-Cutting MeasuresMarch 22, 2024 | seekingalpha.comWhy G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape Get G1 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter. Email Address Look what happened to Netflix during these “Hotspot Dates” (Ad)We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates” But if you want the stock with “Hotspot Dates” hitting NEXT WEEK… GTHX Media Mentions By Week GTHX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GTHX News Sentiment▼0.810.89▲Average Medical News Sentiment GTHX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GTHX Articles This Week▼232▲GTHX Articles Average Week Get G1 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AKBA News Today ALDX News Today DSGN News Today ELYM News Today PYXS News Today GBIO News Today TSVT News Today PRLD News Today OVID News Today ME News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GTHX) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersDigitizing the $11T commodities sector with one tiny stockResource Stock DigestNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss RatingsHe Is Giving Away BitcoinCrypto Swap ProfitsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersElon’s New Device is About to Shock the WorldInvestorPlaceMissed NVDA? Buy this AI stock NOWChaikin AnalyticsThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding G1 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
